Snabbfakta
-
- Paris
Ansök senast: 2024-07-15
Bioinformatician- cancer research (M/ F)
Institut Curie Research CenterInstitut Curie is a major player in the research and fight against cancer. It consists of a Hospital group and a Research Center of more than 1000 employees with a strong international objective of the Research Center is to develop basic research and to use the knowledge produced to improve the diagnosis, prognosis, and therapeutics of cancers as part of the continuum between basic research and innovation serving the LaboratoriesTeam Stress and Cancer - Director: Fatima Mechta-Grigoriou Computational Biology - Director: Hervé Isambert
Project funded by European Commission , in the context of the Horizon Europe program, Mission Cancer 2023.
Title: Assessing the role of intratumoral microbiota in therapy responses using patient-derived tumor-on-chip
Acronym: ARTURO
Resistance to therapies is a major challenge in oncology. Recent research suggests that intratumoral microbiota may contribute to anti-cancer drug resistance, in particular to immunotherapies. However, experimental approaches to address the role of microbiota in human cancers are lacking. Project ARTURO will tackle this problem by using an innovative state-of-the-art 3D tumor-on-chip (ToC) model, as part of the emerging field of Micro-Physiological Systems (MPS). The role of patient-derived bacteria, and of their postbiotics and released extra-cellular vesicles, in tumor ecosystem behaviors and drug responses, will be deciphered by integrating clinical data, omics analysis, and novel ToC-based information (by live imaging and single-cell transcriptomics). The development of advanced computational methods to extract ToC-based information constitutes a major force and innovation in the field, with high potential to accelerate future applications of ToC technology in clinics. The focus will be on two frequent poorly-understood cancer subtypes: non-small cell lung cancer (NSCLC) and invasive lobular breast cancer (ILC).
This interdisciplinary and international project (France, Italy Portugal), coordinated by Maria Carla Parrini, will be developed as collaboration between Institut Curie, Institut Pierre-Gilles de Gennes for microfluidics, Bichat hospital in Paris, Universidade Catolica Portuguesa in Porto, University of TorVergata in Rome, and University of Humanitas in Milan.
Our recent relevant publications
1. Assessing personalized responses to anti-PD-1 treatment using patient-derived lung tumor-on-chip
Veith et al, Cell Rep Med 2024, preprint. doi:
2. CausalXtract: a flexible pipeline to extract causal effects from live-cell time-lapse imaging data
Simon et al, eLife 2024, preprint. doi:
3. Deciphering the spatial landscape and plasticity of immunosuppressive fibroblasts in breast cancer
Croizer et al, Nat Commun 2024 Apr 1;15(1):2806. doi:
Training and skills required
We are seeking for a Bioinformatician at pre-doctoral or post-doctoral level with:
- keen interest to analyze complex heterogeneous biological data
- prior experience in the analysis of sequencing data (RNA-Seq from bulk, single-cell and/or spatial transcriptomic)
- competence in handling high-dimensional -omics data
- proficiency in high-level languages like Python or R and in good coding practices
- image analysis skills (it would be a plus).
- The development of a PhD project on the subject is an open possibility.
Abilities
Autonomy, organizational capacity, team spirit, adaptability to multidisciplinarity, fluency in English.
All our opportunities are open to people with disabilities.
Contract information
Type of contract : fixed-term contract
Starting date: position available immediately
Duration : 3 years
Working time : full time
Remuneration : according to the current grids
Benefits : collective catering, reimbursement of transportation fees up to 70%, supplementary health insurance
Location of the position : Institut Curie, 23 rue d’Ulm, 75005 Paris
Please send your CV, motivation letter and at least 2 reference letters
Deadline for application: 31/07/2024
Institut Curie is an inclusive, equal opportunity employer
and is dedicated to the highest standards of research integrity
